Stephen Liu: Anticipating Global Access to Sunvozertinib in EGFR Exon 20 NSCLC
Stephen Liu/X

Stephen Liu: Anticipating Global Access to Sunvozertinib in EGFR Exon 20 NSCLC

Stephen Liu,  Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared on X:

“Summary of sunvozertinib for EGFR exon 20 NSCLC – now hopefully will gain access after AstraZeneca has acquired global rights. Looking forward to having this as an option soon…

Read more.”

Other articles featuring Stephen V Liu on OncoDaily.